This federal contract award, identified as SPE2DB24D8001|SPE2DB25FKYUV, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $8,500.69 firm fixed-price delivery order is for the pharmaceutical product Dupixent 300 mg/2 ml Pen, with a completion date of November 5, 2024.
Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, valued at $999,999,999.00, as part of the ECAT Generation V Program. This IDC, which extends through December 31, 2025, allows the company to provide a wide range of pharmaceutical products, medical supplies, and healthcare equipment to support U.S. Armed Forces medical operations. The current delivery order is not designated as a set-aside contract.
Generated 2/3/25, 1:13 PM